Connect with us

Cannabis News

New Hampshire Lawmakers Take Up Bipartisan Bills To Legalize Psilocybin For Medical Use

Published

on

New Hampshire lawmakers on Wednesday took up a pair of bipartisan bills to legalize the regulated use of psilocybin for medical purposes.

At a hearing before the House Health, Human Services and Aging Committee, members heard public testimony on the proposals: HB 1809 by Rep. Buzz Scherr (D) and HB 1796 by Rep. Michael Moffett (R).

Both measures seek to create a regulatory pathway for patients with certain conditions to access psychedelics for therapeutic use through a program overseen by the state Department of Health and Human Services (DHHS). But Moffett’s legislation has more mandates about the regulatory framework.

“I’m hardly a major supporter of a measure like this,” Moffett told lawmakers at the hearing, saying he’s “always been very wary and skeptical” of psychedelics and has “always been averse to marijuana for many reasons, including the fact that I was constantly drug tested over many years in the Marine Corps and developed zero tolerance for illegal drug use.”

He said he changed his mind after seeing a presentation on psychedelic therapies at a national veterans conference last summer, where he learned that “a psilocybin treatment option can work for almost anyone, beyond military or ex-military.”

Scher, for his part, said that “a large amount of research is currently being done on the therapeutic uses of psilocybin.”

“Research to help those with treatment-resistant depression is pretty important right now,” he said. “Research is being developed on its broader use for those suffering from other types of PTSD. Research is also being developed on its use with people with other types of substance abuse.”

Jenny O’Higgins of the state Department of Health and Human Services said officials have some concerns about the lack of matching funds in Moffett’s legislation, saying the department “wouldn’t be able to absorb” the program under its current budget.

A representative of Smart Approaches to Marijuana’s New Hampshire affiliate testified against the proposals, saying psilocybin is an illegal Schedule I drug. He also argued that there is insufficient evidence to support the therapeutic potential of psychedelics.




Here are the main provisions HB 1809:

  • DHHS would be responsible for approving licensed medical professionals who are able to act as psilocybin providers for patients.
  • To qualify for the program, patients must be diagnosed with treatment-resistant depression, post-traumatic stress disorder (PTSD), substance use disorder, or another condition approved by an advisory board and DHHS.
  • The legislation specifically states that only natural psilocybin could be administered, excluding synthetic versions of the psychedelic.
  • Suppliers would also have to be approved by the department to grow and harvest their psilocybin products.
  • The process of treating qualifying patients with psychedelics should include a preparation session, an administration session, and an integration session.
  • A Medical Psilocybin Advisory Committee would be established, consisting of a DHHS representative, a qualified patient, a veterans advocate, and eight medical professionals.
    • Those medical experts should include a psychedelic researcher, two regulators overseeing existing medical psilocybin programs, and specialists in addiction treatment, palliative care, veterans affairs, naturopathy, nursing and mental health counseling.
  • The commission would look at DHHS’ data on patient outcomes, add requirements for participation in the program and decide whether to expand the law.
  • The program would be implemented if the advisory committee, within two years of the bill’s passage, notifies lawmakers, regulators and the governor that it can be effectively administered.

“The medical community has always recognized that patients have serious conditions that are highly resistant to effective treatments,” reads a statement of purpose for the measure. “Recently, studies have begun to show that some of these patients have had positive outcomes with closely supervised use of psilocybin for treatment.”

“Patients with significant post-traumatic stress disorder, treatment-resistant clinical depression, and severe substance use disorder have been shown to benefit from controlled, therapeutic use of psilocybin in a supervised setting,” he says. “The purpose of this action is to create a carefully controlled and closely supervised environment in which an approved medical provider can treat a carefully selected patient with appropriate doses of psilocybin produced by the same provider for a medical intervention.”

Here are the main details HB 1796:

  • The bill would allow for the regulated use of psilocybin in a medically supervised setting, and DHHS would be responsible for overseeing the program.
  • To be eligible for psilocybin treatment, a patient 21 years of age or older must be diagnosed with treatment-resistant depression, PTSD, substance abuse disorder, a terminal illness requiring end-of-life care, or any other condition authorized by DHHS.
  • A Psilocybin Licensing Board under the department will be responsible for licensing independent medical psilocybin suppliers, therapy providers, cultivation and testing laboratories.
  • There would be specific guidelines for facilities where psychedelics can be administered, including safety requirements and other safety protocols, such as ensuring that rescue medication is on site in case a patient experiences an adverse event.
  • The legislation would also establish a Psilocybin Therapeutic Treatment Fund, which would be funded by revenue from licensing taxes and fees. The funds would go towards studies on the possibility of expanding the program to include additional psychedelics in the program.
  • If the law is approved, it would take effect on January 1, 2027.

“The purpose of the Therapeutic Psilocybin Act is to allow the beneficial use of psilocybin for the relief of qualified medical conditions in a regulated system,” the bill’s purpose statement reads.

The chances of the bill moving forward this session are unclear, but lawmakers have become increasingly active in recent years in support of psychedelic reform.

Last June, the New Hampshire Senate voted to repeal the compromise legislation It would lower the state’s criminal penalty for first-time possession of psilocybin also creating mandatory minimum sentences for fentanyl.

As originally introduced, the legislation would completely remove the penalties for obtaining, purchasing, transporting, possessing or using psilocybin, effectively legalizing it on an off-trade basis. However a The House Committee amended the bill before it could advance unanimously last march

Meanwhile in New Hampshire, the House last week passed a bill to legalize marijuana in the state– Although his chances of passing to the Senate remain doubtful, and the governor has expressed a clear position against the reform.

Also last week, the chamber approved a proposal to make medical cannabis dispensaries into non-profit businesses.

The legalization bill sponsored by Rep. Jared Sullivan (D) is one of several cannabis proposals filed for the 2026 session, including legislation by Rep. Jonah Wheeler (D) that seeks to put a constitutional amendment on the state ballot. let voters decide whether they want to legalize marijuana for adults 21 and older“having a modest amount of cannabis for their personal use.”

Gov. Kelly Ayotte (R) has already threatened to veto the legalization bill that reaches his desk, even though the proposal to amend the Constitution would not require gubernatorial action.

The governor said in August his position on the reform it would not change, even if the federal government moved forward with reorganizing the plant. Since then, President Donald Trump has ordered the attorney general to complete the process of moving cannabis from Schedule I to III of the Controlled Substances Act (CSA).

At a committee meeting last year, Sullivan ultimately made a persuasive argument for moving forward with his legalization bill, pointing out. The House has repeatedly passed similar legislation and that the House should stand its ground, forcing the Senate and the governor to once again oppose a policy that is popular with voters.

“We know where it’s going. Let’s send a virtue signal,” Sullivan said. “Let them be the ones to piss off the voters who care about this.”

Meanwhile, the House also passed a bill by Rep. Wendy Thomas (D) last week allow medical marijuana dispensaries (known in the state as “alternative treatment centers” or ATCs) to convert their dispensary licenses into nonprofit entities.. HB 54, which adopted a concurrence schedule with other laws, had previously advanced unanimously out of the House Finance Committee.

Part of the motivation behind the legislation is the fact that medical marijuana dispensaries are not for-profit federal states. But in the state, they are considered non-profit organizations, which has disproportionately increased their operating costs.

Other bills introduced in 2026 include two proposals to protect the gun rights of medical cannabis patients.

There’s also some legislation aimed at regulating the sale of hemp, an issue that’s getting a lot of attention since Congress passed and Trump signed an appropriations bill that would effectively re-criminalize most consumable hemp products.

Meanwhile, after the House added provisions to a bill passed by the Senate last year that would have allowed medical marijuana patients to grow cannabis at home, those measures were removed in the conference.

user photo CostaPPR.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

“UK medical cannabis is maturing”

Published

on

By

The UK cannabis market has grown steadily over the past five years, although not always in the way operators had hoped. New brands and imported products have driven much of the expansion, while domestic cultivation has slowed. Alexander Mountain has seen this from the inside long before most people in the industry knew it existed. “I’ve been waiting for this since 2009,” says the founder of growing consultancy Trichome Solutions.

Regulations, compliance, EU-GMP requirements, all of which have made getting a facility off the ground a multi-year exercise. “I’ve worked with organizations and seen firsthand that it takes three, four, even five years to get going,” says Alexander. “It’s a tough market to break into in the UK, which in itself slows down the overall maturation.” The last six months, however, have brought about a change. “There are now clear goals and programs for business. An almost militant approach to protocols. It’s starting to feel like the rest of the EU and Canada.”

© Trichome Solutions

Capitalization and cultivation
Early investment in cannabis in the UK came largely from private capital, and the gap between capitalization and cultivation know-how cost many operators dearly. Consultants were brought in to design and build the facilities, but rarely stayed to operate them. The result was a facility that had to be rebuilt almost as soon as it opened. “A lot of adjustments, changes in workflows, logistical expansion,” says Alexander. “This, of course, requires more capital. This delays profitability and, in some cases, leads to employee burnout.” The model he believes in is the owner-operator structure that has worked in markets such as the US, Canada and Thailand.

In terms of cultivation, genetic selection and post-harvest are where Alexander gives most of his attention. Seasonal changes in the UK favor indoor parameters where possible, although low-light greenhouses have worked for some operators with adequate supplementary lighting. Getting the right genetics for the specific market drives early success and patient retention. Post-harvest, however, he believes the sector is constantly underestimating. “I focus a lot on preserving the plant material and maintaining its chemical profile, particularly cannabinoids, terpenes and volatile sulfur,” he says. “Even simple things, like having enough space to dry properly, seem like common sense. But unless you’ve actually done it, you don’t always realize how important those details are to the quality of the final product.”

UK cannabis demand
Patient demand in the UK has been shaped by the equity market, and licensed operators are working to close this gap. The dynamics here are different from other markets. In Germany and Canada, THC content drives purchasing decisions. In the UK, Alexander is seeing more focus on taste, aromas and the overall experience. “With the amount of choices coming in through imports, people are finding their own strains and becoming more selective,” he says. Closing this gap, in his opinion, involves the farmers as much as the prescribers. “Patient education and support should come from doctors. Producers should teach them about their products. I think growers should invite prescribers more often.”

Over the next three to five years, Alexander expects reliance on imports to ease as domestic supply chains develop and the market stabilizes. He says that there will be operators who come out from the other side, specialized ones. R&D, heritage genetics, premium indoor and post-harvest optimization. “We are now working in the international cannabis industry,” he says. “With comparisons, going on a flight, there is no room for complacency. The operators who find their niche and really excel in it will be the ones who build a strong identity and remain competitive in the cannabis space.”

For more information:
Trichoma solutions
(email protected)
trichomesolutions.com
Linkedin
Instagram

Continue Reading

Cannabis News

DC Mayor Proposes To Let Medical Marijuana And Alcohol Companies Partner On THC Drinks

Published

on

By

The mayor of Washington DC is proposing medical marijuana companies partner with local breweries and distilleries to produce cannabis-infused and non-alcoholic beverages for sale in the nation’s capital.

Under the partnership envisioned by Mayor Muriel Bowser’s (D) Medical Cannabis Beverage Products Amendment Act of 2026, alcohol companies can apply for a medical cannabis production endorsement at a cost of $500 per year to manufacture cannabis beverages, and medical marijuana companies can apply for a $1,000 annual endorsement to import cannabinoids for production.

All beverages would have to be tested by a locally licensed laboratory, and there would be a six percent sales tax on beverages.

“This is an opportunity to support two local industries and keep businesses in DC,” Bowser said in a press release. “We have great local brewers and distillers in our city, we have a strong medical cannabis market, and this is a new opportunity for those two markets to collaborate and create a safe, smoke-free alternative for DC patients”

Breweries and distilleries would not be able to sell cannabis beverages directly to consumers, and the finished products would instead go to medical marijuana manufacturers for testing and distribution.

Sales would be limited to registered medical cannabis patients through dispensaries, and drinks could not be purchased at bars, restaurants, liquor stores and grocery stores.

“It makes sense for the District’s medical cannabis and alcohol manufacturing industries to collaborate to produce medicinal cannabis beverages,” said Fred Moosally, director of the Alcoholic Beverages and Cannabis Administration. he said. “Providing a legal way for our local breweries and distilleries to use their expertise in beverage production is the next step in reaching DC’s medical cannabis market and supporting our local business ecosystem.”

A press release from the mayor’s office said the proposal “works to solve the manufacturing challenges of the medical cannabis industry while providing additional revenue for DC’s local craft beverage producers.”

“Using the existing local bottling infrastructure, DC will expand smokeless therapeutic options for medical cannabis patients, provide additional revenue for the local industry and continue to grow the District’s economy,” he said.

The legislation is now before the District of Columbia Council for consideration.

Although Congress has consistently blocked DC’s legalization of recreational marijuana sales with a pilot approved each year, local officials have worked. expand access through the existing cannabis market for example, allowing residents and even visiting tourists to self-certify without the need for a medical recommendation.

Marihuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

We’re a small grow, which means we can control things very well

Published

on

By

At 5,000 square feet, Flora Arbor is about as small as a licensed cannabis grower can legally get. That’s not the problem the company is trying to solve. “We’re a very small breed, which means we can control things very well.” he says David Myrowitz, director of cultivation. “It also means that we have to be successful in every round.” Three flower cells, collected in three weeks. There is no such thing as a bad lot to disappear into a larger average. Every shift counts, and the operation is built around that reality.

It starts in the pump room
Reverse osmosis water is fed into holding tanks, nutrients are mixed by an Agrowtek fertigation machine, and the entire system runs from a GCX controller that monitors moisture sensors, dissolved solids, and soil temperature in every room. Canopy sensors feed directly into HVAC, which Flora Arbor runs on Cultiva units. “If you talk to any grower, any grower, they’ll tell you the number one thing for successful growing is having a good HVAC system,” says David. “There is somewhere that we don’t have expenses.”

© Flora Arbor

Genetics and cells
Mother plants are removed every three to six months, so cuttings are always taken from young stock. The clones move from the humidity domes to a humidity-controlled room, then to the vegetables, where a crop-correction protocol runs several irrigation streams per day to encourage growth. Moisture sensors in the grow bags track each drying cycle, and daily watering patterns are revised based on the goals of the grow system.

The flower rooms have a double-level system, with taller plants at the bottom, shorter ones at the top, grouped to keep microclimates outside and an even distribution of light. The second mesh is lowered as the plants develop to give each bud site its own square and keep airflow moving through the canopy.

In a recent route, rooms from different phases of the cycle were working at the same time. Hawaiian Rain has been crossed with permanent marker, disk chips, cereal milk. David pointed to the development of crystals in the Hawaiian Rain cross, the citrus resin charge of Disco Fries, the height management challenge of pushing a cultivar as high as possible without burning them in the lights. “We try to have a nice spread of genetics, a nice representative of each flavor profile and effect, to make sure everyone can get something they like,” he says.

Crossing the finish line
Post-harvest is managed at home, by hand. The product is sorted on the cutting table A-Bd, B-Bud and cutting table, strictly separated, the grade on the label means something. The tiered structure also serves a second purpose. “We think it’s really important to make sure quality flowers are available to people of all means, not just people who can afford the premium,” says David. The three-week harvest cycle is Flora Arbor’s main argument for the consumer. Small batches, constant rotation, nothing stored.

“Every time you get a bag, it’s going to be fresh, freshly picked grass,” says David. “It’s not something that’s been sitting in some MSO’s vault for six months because they’ve collected 2,000 pounds and can’t sell it.” The bet is that in a market where no one has solved the consistency complaint, being small enough to catch all the cattle is more valuable than the economies of scale you allow to get there.

For more information:
Flora Arbor
1300 Abbott Dr, Elgin, IL 60123
847-504-8450
(email protected)
floraarbor.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media